Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors

16 novembre 2026 mis à jour par: BioNTech SE

A Phase I/II, First-in-human, Open-label, Multi-site, Dose Escalation and Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNT3211 in Participants With Advanced Solid Tumors

This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Description détaillée

This study will consist of two parts (A and B). Part A will be a dose escalation to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BNT3211. Part B will be a dose optimization and proof-of-concept to further investigate the safety, tolerability and preliminarily antitumor activity of BNT3211 at doses selected from Part A. Part B will enroll participants with the same indications as in Part A.

No randomization will be performed in Part A. In Part B, for each selected indication, participants are randomized to the doses selected at the end of Part A using a dynamic allocation procedure.

There will be a screening period, a treatment period, and a follow-up period (including an end-of-treatment visit, a safety follow-up visit, and a survival follow-up period with regular visits).

Participants will receive BNT3211 until disease progression, start of new anticancer treatment, unacceptable toxicity, withdrawal of consent, or until the sponsor terminates the study or any other criterion for discontinuation is met.

Type d'étude

Interventionnel

Inscription (Estimé)

345

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: BioNTech clinical trials patient information
  • Numéro de téléphone: +49 6131 9084
  • E-mail: patients@biontech.de

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

  • Are ≥18 years of age (local laws will be followed if the age of consent is older).
  • Have an Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Have a life expectancy of ≥3 months in the opinion of the investigator.
  • Have at least one measurable lesion as per RECIST v1.1.
  • Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
  • Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least first-line SoC therapy prior to enrollment.
  • Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
  • Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.

Key Exclusion Criteria:

  • Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.

  • Have had prior allogeneic bone marrow transplantation or solid-organ transplantation.

  • Have had an inadequate washout period for prior anticancer treatment or other restricted medications prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.

  • Have received systemic steroids (>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.

  • Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.

  • Have a history of leptomeningeal carcinomatosis.

  • Have brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.

  • Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.

  • Have clinically significant concomitant pulmonary disease, including but not limited to: chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.

  • Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).

  • Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.

  • Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.

  • Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.

  • Have a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Protocol defined exceptions apply.

  • Have any other primary malignancy within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.

  • Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).

  • Have any of the following heart conditions within 6 months prior to the study treatment:

    • Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
    • New York Heart Association functional classification ≥II heart failure or LVEF <50%.
    • Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
    • Mean QT interval corrected by Fridericia's method >450 ms for males or >470 ms for females in three successive screening measurements based on a 12-lead electrocardiogram.
  • Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.

Note: Other protocol defined inclusion and exclusion criteria apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part A (dose escalation) - BNT3211 monotherapy

Escalating dose levels of BNT3211.

Intravenous infusion

Expérimental: Part B (dose optimization) - BNT3211 monotherapy

Indications as in Part A. Doses will be selected from Part A.

Intravenous infusion

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
Délai: Up to 21 days from the initiation of first dose of BNT3211

DLT period defined as the first 21 days. Per dose level.

Up to 21 days from the initiation of first dose of BNT3211
Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs
Délai: From first dose until 35 days after the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs
Délai: From the first until the last dose of BNT3211 (up to 36 months)

Per dose level (Part A) and per arm (Part B).

From the first until the last dose of BNT3211 (up to 36 months)
Part B only - Objective response rate
Délai: Up to 36 months

Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] based on the investigator's assessment) is observed as best overall response. Per arm.

Up to 36 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Délai: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Délai: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Délai: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
Délai: Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)

After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits.

Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
Part A only - Objective response rate
Délai: Up to 36 months

Defined as the proportion of participants with confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per dose level.

Up to 36 months
Disease control rate
Délai: Up to 36 months

Defined as the proportion of participants in whom a confirmed CR, confirmed PR or stable disease (SD) (per RECIST v1.1 based on the investigator's assessment, SD assessed at least 6 weeks [±7 days] after the first BNT3211 dose) is observed as best overall response. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Duration of response
Délai: Up to 36 months

Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. Per dose level (Part A) and per arm (Part B).

Up to 36 months
Part B only - Progression free survival
Délai: Up to 36 months

Defined as the time from first dose of BNT3211 to first objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment), or death from any cause, whichever occurs first. Per arm.

Up to 36 months
Part B only - Overall survival
Délai: Up to 36 months

Defined as the time from first dose of BNT3211 to death from any cause. Per arm.

Up to 36 months
Anti-drug antibody prevalence
Délai: For up to 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants who are anti-drug antibody positive (either baseline or post-baseline). Per dose level (Part A) and per arm (Part B). As data permits.

For up to 35 days from the last dose of BNT3211 (up to 36 months)
Anti-drug antibody incidence
Délai: For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

Defined as proportion of participants having treatment-emergent anti-drug antibodies. Per dose level (Part A) and per arm (Part B). As data permits.

For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: BioNTech Responsible Person, BioNTech SE

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 octobre 2029

Achèvement de l'étude (Estimé)

1 mars 2030

Dates d'inscription aux études

Première soumission

16 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • BNT3211-01

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner